Evolutionary distances were estimated with DNADIST (Kimura two-parameter method) and phylogenetic relationship were determined by NEIGHBOR (neighbour-joining method).
Reproducibility of trees was evaluated using SEQBOOT (1000 replicates) and CONSENSE. Trees were constructed using FigTree. Programs were run with default parameters.
The patient was tested for HIV-1 Ab Elisa and Western Blot in March 2012 in Milan with a positive result. Our results indicate that the salvage treatment was successful in this patient despite his background of resistance to almost all NRTIs and NNRTIs.
As for the DRV/r plus RAL combination, Akil Jackson et al. carried out a study which analyzed DRV/r and RAL plasma and intracellular concentrations in HIV-infected individuals during coadministration. In this study, HIV-infected patients on antiretroviral therapy received RAL 400 mg twice daily for 21 days; DRV/r 800/100 mg once daily was added for 14 days and patients were randomized to continue RAL twice daily or to switch to 800 mg once daily, then they all stopped RAL intake and continued DRV/r once daily for 14 days. Notwithstanding the difficult virological presentation, complicated by HBV co-infection, we designed an effective treatment combination that included RAL+DRV/r+TDF with the aid of precise molecular tools. Our patient presented a sustained immunological and virological response overcoming difficulties posed by a complex CXCR4-tropic CRF11-cpx virus.
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Reproducibility of trees was evaluated using SEQBOOT (1000 replicates) and CONSENSE. Trees were constructed using FigTree. Programs were run with default parameters. In June 2012, he was tested for HBsAg with a positive result, up to 125,000 copies/ml (68 CD4cells/µL; 3.5%) . In July 2012, he had a viral load referred as HBV-DNA equal to 720,000 copies/mL (82 CD4cells/ µL; 3.0%) and tenofovir was added to the other antiretrovirals. In
September 2012, the HBV-DNA decreased to 139,445 copies/mL (114 cells/µL; 4.4%). In
November 2012, the HBsAg load was 65079,59 copies/mL and HBV-DNA was 19,604 copies/mL (154 CD4 cells/µL; 6.1%). In February 2013, HBV-DNA was 627 copies/mL (142 CD4cells/µL; 8.4%). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Our results indicate that the salvage treatment was successful in this patient despite his background of resistance to almost all NRTIs and NNRTIs.
As for the DRV/r plus RAL combination, Akil Jackson et al. carried out a study which analyzed DRV/r and RAL plasma and intracellular concentrations in HIV-infected individuals during coadministration. In this study, HIV-infected patients on antiretroviral therapy received RAL 400 mg twice daily for 21 days; DRV/r 800/100 mg once daily was added for 14 days and patients were randomized to continue RAL twice daily or to switch to 800 mg once daily, then they all stopped RAL intake and continued DRV/r once daily for 14 days. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 , while the reviewer used a FPR cut-off of 1%: for this reason we concluded that patient harbours a CXCR4-tropic virus. Moreover, the reviewer changed the sequence with accession number KF381391: all ambiguity codes were substituted with N code (as reported in the geno2pheno report attached by the reviewers). These changes resulted in several aminoacids substitutions, that affected and worsened the geno2pheno interpretation. Ambiguity are usually present in HIV sequences (especially in the gp120 hypervariable domains), owing to the high heterogeneity and variability of viral population. In our opinion, we would not modify the referenced sequence, thus introducing aminoacids changes not present in our original sequence and indeed in the sample (i.e.: in our sequence the 11th codon is AGY, coding for Ser for both AGT and AGC; in the reviewers sequence at the same position it is reported a AGN codon, that could encode Ser for AGT and AGC and Arg for AGA and AGG).
2) The drug resistance profile reported for this patient does not match the results I get using 6) The authors should use the "Subtype Reference Alignment" with nonrecombinants plus CRF11_cpx sequences. The paper states that the complete genome alignment was used, but there are hundreds of complete genomes in the LANL HIV genome alignment, and a very few have been carefully chosen for "references". http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html The phylogenetic tree is acceptable as it is, this paper is not primarily about the phylogeny, so just clarifying that the subtype reference alignment was used, should be sufficient. We agree with the reviewer.
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